Department of Large Animal Clinical Sciences, University of Saskatchewan, Saskatoon, Canada.
Anim Reprod Sci. 2009 Nov;116(1-2):107-18. doi: 10.1016/j.anireprosci.2008.12.008. Epub 2008 Dec 24.
The objective was to compare the reproductive performances associated with the first (Cycle-1), second (Cycle-2), and mid-season (MS-Cycle) ovulations of the breeding season in donor mares that were treated with equine-FSH (eFSH) in the early vernal transition. Mares (n=15) kept under ambient light were examined ultrasonographically per-rectum starting January 30. When an ovarian follicle > or =25mm in diameter was detected, twice daily eFSH treatments were initiated. The eFSH treatments ceased when a follicle > or =35mm was detected, and 36h later hCG was administered. Thereafter, mares were artificially inseminated every 48h until ovulation (Day 0). Trans-cervical embryo recovery attempts were performed on Day 8, and subsequently PGF2alpha was administered. Equine FSH was not administered in the subsequent estrous cycles. In Cycle-2 and in the MS-Cycle, hCG was administered when a follicle > or =35mm was detected; breeding, embryo recovery, and PGF2alpha administration, were similar to Cycle-1. Mares had an untreated estrous cycle (no treatment or breeding) between Cycle-2 and the MS-Cycle. All mares developed follicle(s) > or =35mm after 4.9+/-0.6 days of eFSH treatment, and subsequently ovulations occurred; mean (95% CI) interval from treatment initiation to ovulation was 7.9 (6.5-9.3) days. The number of preovulatory follicles (> or =30mm) at the time of hCG administration (Cycle-1: 2.2+/-0.3 compared with Cycle-2: 1.0+/-0 compared with MS-Cycle: 1.1+/-0.1 follicles), and the number of ovulations (2.5+/-0.4 compared with 1.0+/-0 compared with 1.1+/-0.1 ovulations) were greater (p<0.05) in Cycle-1. Nevertheless, mean embryo numbers did not differ among cycles (0.8+/-0.2 compared with 0.5+/-0.1 compared with 0.5+/-0.1 embryo/mare). On average, embryo morphology grade was less (p<0.05) in Cycle-1 as compared to non-eFSH cycles (combined Cycle-2 and MS-Cycle). This impaired embryo quality could be due to a seasonal effect, or negative effect of the eFSH treatment, which was possibly related to alterations in the hormonal environment (estradiol-17beta and progesterone). A prolonged IOI (>21 days) was recorded in 7 of 15 mares following the Cycle-1 ovulation, but not subsequently. In conclusion, eFSH treatment of vernal transitional donor mares stimulated ovulation within only few days of treatment, and the following embryo recovery rate was at least as good as in the subsequent estrous cycles; however, on average, embryos were morphologically impaired. In subsequent estrous cycles in the breeding season, ovulations, embryo recovery rates, and embryo variables did not appear to be negatively affected; however, the first inter-ovulatory interval of the breeding season was prolonged in approximately half of the mares.
本研究的目的是比较在春季过渡早期用马促卵泡素(eFSH)处理的供体母马的第一次(Cycle-1)、第二次(Cycle-2)和中期(MS-Cycle)排卵的繁殖性能。15 匹母马在环境光照下饲养,从 1 月 30 日开始经直肠超声检查。当检测到直径大于或等于 25mm 的卵泡时,每天两次开始给予 eFSH 治疗。当检测到卵泡大于或等于 35mm 时,停止 eFSH 治疗,并在 36 小时后给予 hCG。此后,每隔 48 小时对母马进行人工授精,直到排卵(第 0 天)。第 8 天进行经宫颈胚胎回收尝试,随后给予 PGF2alpha。在随后的发情周期中不再给予马促卵泡素。在 Cycle-2 和 MS-Cycle 中,当检测到卵泡大于或等于 35mm 时给予 hCG;配种、胚胎回收和 PGF2alpha 给药与 Cycle-1 相似。在 Cycle-2 和 MS-Cycle 之间,母马有一个未经处理的发情周期(无治疗或配种)。所有母马在接受 eFSH 治疗 4.9+/-0.6 天后均出现卵泡大于或等于 35mm,并随后排卵;从治疗开始到排卵的平均(95%CI)间隔为 7.9(6.5-9.3)天。在给予 hCG 时,发情周期的促黄体生成素处理前排卵卵泡(>或等于 30mm)的数量(Cycle-1:2.2+/-0.3 与 Cycle-2:1.0+/-0 与 MS-Cycle:1.1+/-0.1 个卵泡)和排卵数量(2.5+/-0.4 与 1.0+/-0 与 1.1+/-0.1 个排卵)在 Cycle-1 中更大(p<0.05)。然而,在周期之间胚胎数量没有差异(0.8+/-0.2 与 0.5+/-0.1 与 0.5+/-0.1 胚胎/母马)。平均而言,胚胎形态学评分在 Cycle-1 中较低(p<0.05)与非 eFSH 周期(Cycle-2 和 MS-Cycle 合并)相比。这种胚胎质量受损可能是由于季节性影响,或 eFSH 治疗的负面影响,这可能与激素环境的改变(雌二醇-17β和孕酮)有关。在 Cycle-1 排卵后,15 匹母马中有 7 匹记录到 IOI 延长(>21 天),但随后没有记录到。总之,用 eFSH 处理春季过渡期的供体母马可在治疗后几天内刺激排卵,随后的胚胎回收率至少与随后的发情周期一样好;然而,平均而言,胚胎在形态上受损。在随后的发情周期中,排卵、胚胎回收率和胚胎变量似乎没有受到负面影响;然而,在大约一半的母马中,第一次排卵间隔延长。